RxSight cuts 2026 sales outlook, citing competitive headwinds
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St futures ease as Big Tech earnings rekindle AI spending worries, oil jumps
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits fresh 40-year high versus yen, edges higher against euro
RxSight Inc. (RXST) PT Lowered to $6.50 at BofA Securities
July 7, 2026 12:24 PM EDTBofA Securities analyst Craig Bijou lowered the price target on RxSight Inc. (NASDAQ: RXST) to $6.50 (from $8.00) while maintaining a Underperform rating.
The analyst comments "RXST pre-Ad preliminary Q2 sales of $27m vs Street of $32m and lowered 2026 guidance by $13m at... More
